Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence
of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation …

In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic
recommendations for the preclinical, mild cognitive impairment, and dementia stages of …

Apolipoprotein E (apoE) alleles determine the age-adjusted relative risk (ɛ4 > ɛ3) for
Alzheimer's disease (AD). ApoE may affect AD pathogenesis by promoting deposition of the …

Alzheimer’s disease (AD) was first described a little more than 100 years ago. It is the most
common cause of dementia with an estimated prevalence of 30 million people worldwide, a …

The deposition of amyloid-β (Aβ) peptides into amyloid plaques precedes the cognitive
dysfunction of Alzheimer's disease (AD) by years. Biomarkers indicative of brain amyloid burden …

Amyloid-β (Aβ) accumulation in the brain extracellular space is a hallmark of Alzheimer’s
disease. The factors regulating this process are only partly understood. Aβ aggregation is a …

Objectives Amyloid‐β 42 (Aβ 42 ) appears central to Alzheimer's disease (AD) pathogenesis
and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Aβ 42 is …

APOE4 is the strongest genetic risk factor for late-onset Alzheimer disease. ApoE4 increases
brain amyloid-β pathology relative to other ApoE isoforms 1 . However, whether APOE …

Amyloid-β (Aβ) plaque deposition in specific brain regions is a pathological hallmark of
Alzheimer's disease. However, the mechanism underlying the regional vulnerability to Aβ …

Certain disease states are characterized by disturbances in production, accumulation or
clearance of protein. In Alzheimer disease, accumulation of amyloid-β (Aβ) in the brain and …